BioPharma Resources

Drug Trial Radar · NCT04849728

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Aug 19, 2021

Primary completion

Sep 29, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Inventiva PharmaIndustry
Sponsor type
Industry
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • IVA337Drug

    A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.

  • PlaceboDrug

    A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Resolution of NASH and improvement of fibrosisTime frame: Part A: Date of randomisation until the date of biopsy at Week 72
  2. Safety AnalysesTime frame: 48 weeks after completion of DBPC period

Locations

459 sites in 24 countries. Site status is shown where the registry gives one.

  • Objective Health - Birmingham Gastroenterology Associates

    Birmingham, Alabama

  • Digestive Health Specialist of the Southeast

    Dothan, Alabama

  • North Alabama GI Research Center llc

    Madison, Alabama

  • The Institute For Liver Health - Chandler

    Chandler, Arizona

  • Arizona Liver Health - Peoria

    Peoria, Arizona

  • Dignity Health - St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Saint Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Adobe Gastroenterology

    Tucson, Arizona

  • Arizona Liver Health

    Tucson, Arizona

  • ARcare Center for Clinical Research - Conway

    Conway, Arkansas

  • ARcare Center for Clinical Research

    Little Rock, Arkansas

  • Arkansas Diagnostic Center

    Little Rock, Arkansas

  • Arkansas Gastroenterology

    North Little Rock, Arkansas

  • Summit - Arkansas Gastroenterology

    North Little Rock, Arkansas

  • Fomatmedicalresearch

    Camarillo, California

  • GW Research

    Chula Vista, California

  • Velocity Clinical Research, Chula Vista

    Chula Vista, California

  • TriWest Research Associates

    El Cajon, California

  • Cure Clinical Research, LLC

    Fountain Valley, California

  • SC Clinical Research

    Garden Grove, California

  • Velocity Clinical Research - Gardena

    Gardena, California

  • National Research Institute - Santa Ana

    Huntington Park, California

  • The Clinical Trials Network - Gastro Care Institute

    Lancaster, California

  • National Research Institute - Westlake

    Los Angeles, California

  • National Research Institute - Panorama City

    Panorama City, California

  • California Liver Reearch

    Pasadena, California

  • Cadena Care Institute

    Poway, California

  • Stanford University Medical Center

    Redwood City, California

  • Research and Education, Inc.

    San Diego, California

  • California Pacific Medical Center Research Institute

    San Francisco, California

  • Quest Clinical Research

    San Francisco, California

  • Silicon Valley Research Institute

    San Jose, California

  • Clinical Trial Management Services

    Thousand Oaks, California

  • San Fernando Valley Health Institute

    Van Nuys, California

  • South Denver Gastroenterology - Swedish Medical Center Office

    Englewood, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Synergy Healthcare

    Bradenton, Florida

  • Florida Research Institute

    Bradenton, Florida

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Gastro Florida

    Clearwater, Florida

Showing 40 of 459 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.